How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy
Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.
Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.